LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Search

Penumbra Inc

Geschlossen

BrancheGesundheitswesen

338.48 -0.53

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

337.48

Max

340.45

Schlüsselkennzahlen

By Trading Economics

Einkommen

-176M

-130M

Verkäufe

31M

385M

KGV

Branchendurchschnitt

81.89

66.845

Gewinnspanne

-33.822

Angestellte

4,700

EBITDA

13M

68M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+9.64% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

22. Apr. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

122M

13B

Vorheriger Eröffnungskurs

339.01

Vorheriger Schlusskurs

338.48

Nachrichtenstimmung

By Acuity

67%

33%

306 / 351 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Penumbra Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Jan. 2026, 13:29 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update

15. Jan. 2026, 12:35 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- Update

15. Jan. 2026, 12:29 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

25. Feb. 2026, 18:02 UTC

Ergebnisse

Penumbra: Won't Be Providing Financial Guidance for 2026, Citing Proposed Boston Scientific Deal

25. Feb. 2026, 18:01 UTC

Ergebnisse

Penumbra 4Q Rev $385.4M >PEN

25. Feb. 2026, 18:01 UTC

Ergebnisse

Penumbra 4Q Adj EPS $1.18 >PEN

25. Feb. 2026, 18:01 UTC

Ergebnisse

Penumbra 4Q EPS $1.20 >PEN

24. Jan. 2026, 06:18 UTC

Akquisitionen, Fusionen, Übernahmen

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

15. Jan. 2026, 14:37 UTC

Heiße Aktien

Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock -- WSJ

15. Jan. 2026, 13:45 UTC

Akquisitionen, Fusionen, Übernahmen

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. -- Barrons.com

15. Jan. 2026, 12:04 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Penumbra Shareholders Can Elect to Receive Cash or Stock >BSX PEN

15. Jan. 2026, 12:03 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Acquisition to Expand Cardiovascular Portfolio >BSX PEN

15. Jan. 2026, 12:01 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific: Penumbra Deal Carriers an Enterprise Value of About $14.5 Billion >BSX

15. Jan. 2026, 12:00 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific to Buy Penumbra for $374/Share >BSX PEN

15. Jan. 2026, 12:00 UTC

Akquisitionen, Fusionen, Übernahmen

Boston Scientific Announces Agreement To Acquire Penumbra, Inc. >BSX PEN

Peer-Vergleich

Kursveränderung

Penumbra Inc Prognose

Kursziel

By TipRanks

9.64% Vorteil

12-Monats-Prognose

Durchschnitt 372.36 USD  9.64%

Hoch 374 USD

Tief 360 USD

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Penumbra Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

15 ratings

3

Buy

12

Halten

0

Sell

Technischer Score

By Trading Central

288.28 / 292.9394Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

306 / 351 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat